The company has not filed an annual or quarterly report since its Q3 FY2019 10-Q, filed May 7, 2019. Its latest SEC filing is a SC 13G/A from Feb 14, 2020.
10-Q for Q3 FY2019, filed May 7, 2019
The sections below describe the company as of the FY2018 annual report.
Develops targeted medicines for cancer and other diseases, and sells BRAFTOVI and MEKTOVI for melanoma through specialty distributors and pharmacies.
10-K for FY2018, filed Aug 14, 2018
Partners pay Array through upfront license fees, research and development funding, milestone payments when specified goals are achieved, and royalties on product sales. Array also earns product-sales revenue when medicines are delivered and receives reimbursement for research costs from partners.
10-K for FY2018, filed Aug 14, 2018We follow ASC 605-25, Revenue Recognition – Multiple-Element Arrangements and ASC 808, Collaborative Arrangements, if applicable, to…View ↗
We typically receive non-refundable, up-front payments when licensing our intellectual property, which often occurs in conjunction with a…View ↗
Most of our agreements provide for non-refundable milestone payments. We recognize revenue that is contingent upon the achievement of a…View ↗
We recognize revenue for the performance of services or the shipment of products when each of the following four criteria is met: (i)…View ↗
We record as revenue amounts received from our license partners for reimbursement of costs we incur where we act as a principal, control…View ↗
$173.8M
10-K for FY2018, filed Aug 14, 2018
$173.8M ↗
In the U.S., specialty distributors and pharmacies handle BRAFTOVI and MEKTOVI and resell them to hospitals, oncology clinics or patients; outside the U.S., regional partners commercialize the medicines in their territories.
10-K for FY2018, filed Aug 14, 2018
No. It lost $147.3M in .
10-K for FY2018, filed Aug 14, 2018
10-Q for Q3 FY2019, filed May 7, 2019
−$37.5MView ↗
8-K, filed Jul 30, 2019
On July 30, 2019, Array (i) notified the Nasdaq Stock Market LLC (“Nasdaq”) of the consummation of the Merger and (ii) requested that…View ↗
8-K, filed Jun 17, 2019
On June 14, 2019, Array BioPharma Inc., a Delaware corporation (“Array”), entered into an Agreement and Plan of Merger (the “Merger…View ↗
Grew. Revenue grew 4.1x in 4 years, from $42.1M in to $173.8M in , about 43% a year.
From pipeline to marketed medicines
The older report presents Array mainly through its drug discovery and clinical-development programs; the latest report also describes U.S. sales of BRAFTOVI and MEKTOVI for melanoma.
10-K for FY2015, filed Aug 21, 2015 10-K for FY2018, filed Aug 14, 2018Array is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat…View ↗
Loading...
